Zomedica Corp. analyst estimates, including ZOM earnings per share estimates and analyst recommendations. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -28.5%. What caused the stock price to increase? About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and … As of 11:33 a.m. EST, the veterinary health company's stock price is up more than 40%. Further, Zomedica Corp. (ZOM) has a beta value of 1.47, and an average true range (ATR) of 0.14. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. Furthermore, Zomedica Corp. (ZOM)’s beta value is 0.94, and its average true range (ATR) is 0.16. As of 12:25 p.m. EST, the veterinary health company's stock price was up more than 24%. If you had invested in Zomedica Corp stock at $2.39, your return over the last 3 years would have been 11.34%, for an annualized return of 3.65%. The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. Stock offerings raise capital that can be used by the company to fund projects and pay down debt. See Zomedica Corp. (ZOM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. ZOMEDICA CORP. earnings per share revisions and analysts forecast | Nyse MKT: ZOM | Nyse MKT View real-time stock prices and stock quotes for a full financial overview. What this means: Zomedica Pharmaceuticals Corp (ZOM) gets an Overall Rank of 67, which is an above average rank under InvestorsObserver's stock ranking system. $1.20. The average equity rating for ZOM stock is currently 2.00, trading closer to a bullish pattern in the stock market. Insiders are in possession of 4.42% of company’s total shares while institution are holding 6.33% percent of that, with stock having share float percentage of 6.62%. Post-Market 0.02 (0.75%) InvestorsObserver Feb 10, 2021, 10:50 ET. The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) has increased by 18.38% today. ZOM is set to launch its Truforma software platform in veterinary offices in March. Zomedica Corp. (ZOM) Analyst Forecasts Analyst recommendations provided by FactSet shows that the consensus forecast for Zomedica Corp. (ZOM) is a “Buy”. In addition, Zomedica Corp. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Analysts have given the company’s stock an average 52-week price target of $1.2, forecast between a low of $1.2 and high of $1.2. NYSEAMERICAN:ZOM has been on the radar lately as one of the meme stocks that was caught Zomedica Stock Has Gotten Out of Hand - InvestorPlace ... 1 Wall Street analysts have issued twelve-month price targets for Zomedica's stock. We expect Zomedica ZOM investors to focus on the outlook for the company’s first commercial product, scheduled to be launched on Mar 30, 2021, when it … Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million. Trading volume of 40.1 million shares made Zomedica's stock the most actively traded ahead of … Zomedica’s product portfolio will include innovative diagnostics and therapeutics that emphasize patient health and practice health. The Investor Relations website contains information about Zomedica Corp.'s business for stockholders, potential investors, and financial analysts. Price Target. Zomedica Corp. (ZOM) estimates and forecasts. News provided by. Zomedica Corp. (NYSE:ZOM) trade information. Zomedica Pharmaceuticals Corp. ZOM 2.66 0.11 (4.31%). 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. Stock analysis for Zomedica Corp (ZOM:NYSEAmerican) including stock price, stock chart, company news, key statistics, fundamentals and company profile. © According to one analyst, the rating for Zomedica stock is "Buy" and the 12-month stock price forecast is 1.20. View Zomedica Corp. ZOM investment & stock information. Thinking about buying stock in Zomedica, Zynerba Pharmaceuticals, Cronos Group, Hexo Corp, or AzurRx BioPharma? Get Zomedica Corp (ZOM:NYSE American) real-time stock quotes, news, price and financial information from CNBC. Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica Corp Stock Price Forecast, "ZOM" Predictons for2021 A high-level overview of Zomedica Corp. (ZOM) stock. Zomedica Corp. (NYSE:ZOM)’s Major holders. Get the latest Zomedica Corp. ZOM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Shares of Zomedica (NYSEMKT: ZOM) hit a new 52-week high on Friday. Headlines. The one-year ZOM stock forecast points to a potential downside of -59.17. To hit the forecast high, the stock’s price needs a +11.11% upsurge from its latest level, while the stock would need to tank 11.11% for it to hit the projected low. Analyst Recommendations. Sporting 21% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jan 05 when the ZOM stock price touched $0.59 or saw a rise of 17.97%. Their forecasts range from $0.30 to $0.30. Guru’s Opinion on Zomedica Corp. [ZOM]: Zomedica Corp. stock was originally listed at a price of $2.39 in Nov 21, 2017. ZOM Stock Performance Analysis: Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.79. Shares of Zomedica Pharmaceuticals (NYSEMKT:ZOM) continued their recent rapid ascent on Tuesday. NYSEAMERICAN:ZOM fell 14.07% on Tuesday despite broader markets hitting new all-time highs once again. ZOM stock forecast Zomedica is preparing to … Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. ... Analyst Forecasts. ZOM’s stock offering valued at $1.90 per share by its underwriter. The median estimate represents a -54.89% decrease from the last price of 2.66. Read More . Shares of Zomedica Corp. tumbled 17.0% in premarket trading Tuesday, after the veterinary health company's common stock offering, that was upsized by nearly seven-fold, priced at a deep discount. Shares of Zomedica (NYSEMKT:ZOM) soared on Monday, extending the veterinary health company's torrid gains in recent days. Find the latest Earnings Report Date for Zomedica Corp. Common Shares (ZOM) at Nasdaq.com. Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company’s stock has been forecasted to trade at an average price of $1.2 over the course of the next 52 weeks, with a low of $1.2 and a high of $1.2. ZOM | Complete Zomedica Corp. stock news by MarketWatch. Zomedica Corp Stock Price Forecast, "ZOM" Predictons for2025 Stock Price Forecast. As of 1:30 p.m. EST, Zomedica's stock … Zomedica appears to … In 2021, company’s earnings growth rate is likely to be around -4.5% while estimates for its earnings growth in next 5 years are of 0%. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. The Average True Range (ATR) for Zomedica Corp. is set at 0.13 The Price to Book ratio for the last quarter was 11.50, with the Price to Cash per share for the same quarter was set at 0.06.